Exchange: NASDAQ·Updated 07:30 PM EST

RXST News

News
all
press releases
RxSight, Inc. (NASDAQ:RXST) Stock Has Consensus Target Price of $6.94 According to Analysts
Shares of RxSight, Inc. (NASDAQ:RXST - Get Free Report) have been assigned a consensus rating of "Hold" from the eleven research firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and tw...
MarketBeat
RxSight, Inc. (NASDAQ:RXST) Stock Has Consensus Target Price of $6.94 According to Analysts
Shares of RxSight, Inc. (NASDAQ:RXST - Get Free Report) have been assigned a consensus rating of "Hold" from the eleven research firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and tw...
MarketBeat
More News
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
RxSight (RXST) delivered earnings and revenue surprises of +27.59% and -10.56%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
RxSight (RXST) delivered earnings and revenue surprises of +47.62% and +2.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
UFP (UFPT) delivered earnings and revenue surprises of +16.34% and +8.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
IQVIA (IQV) delivered earnings and revenue surprises of +4.31% and +1.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.
Zacks
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it is investigating potential claims against the board of directors of RxSight, Inc. (RxSight or the Company) (NASDAQ: RXST) concerning whether the board breached its fiduciary duties to...
Business Wire

Advertisement|Remove ads.